10-Q Filing

BNB PLUS CORP. CIK: 744452 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0001410578-22-001364`
Period End Date	20220331
Filing Date	20220512
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	apdn-20220331x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 67 Income Statement 98 Cash Flow Statement 72 Stockholders Equity 33

Balance Sheet 67 line items

Line Item	Tag	Value	Unit	Period
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$39.82K	USD	Point-in-time
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$29.82K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.55M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.51M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable, net of allowance of $39,821 and $29,821 at March 31, 2022 and September 30, 2021, respectively	`AccountsReceivableNetCurrent`	$2.59M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable, net of allowance of $39,821 and $29,821 at March 31, 2022 and September 30, 2021, respectively	`AccountsReceivableNetCurrent`	$2.80M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$1.37M	USD	Point-in-time
Inventories	`InventoryNet`	$1.41M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$568.88K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$643.97K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$11.30M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$11.16M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$2.63M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	8.23M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	7.49M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.02M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	7.49M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	8.23M	shares	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$95.02K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$95.04K	USD	Point-in-time
Total assets	`Assets`	$13.88M	USD	Point-in-time
Total assets	`Assets`	$14.42M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.99M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.24M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$393.66K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$281.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.63M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.27M	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$31.47K	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$31.47K	USD	Point-in-time
Common Warrant liability	`SharesSubjectToMandatoryRedemptionSettlementTermsAmount`	$2.57M	USD	Point-in-time
Total liabilities	`Liabilities`	$6.23M	USD	Point-in-time
Total liabilities	`Liabilities`	$3.30M	USD	Point-in-time
Commitments and contingencies (Note G)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note G)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2022 and September 30, 2021, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2022 and September 30, 2021, respectively	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of March 31, 2022 and September 30, 2021, 8,234,320 and 7,486,120 shares issued and outstanding as of March 31, 2022 and September 30, 2021, respectively	`CommonStockValue`	$8.24K	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of March 31, 2022 and September 30, 2021, 8,234,320 and 7,486,120 shares issued and outstanding as of March 31, 2022 and September 30, 2021, respectively	`CommonStockValue`	$7.49K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$298.35M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$295.23M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-290.71M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-284.12M	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity:	`StockholdersEquity`	$11.11M	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity:	`StockholdersEquity`	$7.65M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-722.00	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-979.00	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.39M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.62M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.72M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$7.65M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$13.88M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$14.42M	USD	Point-in-time

Income Statement 98 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$2.67M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$4.29M	USD	2 Qtrs
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$6.15M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$10.31M	USD	2 Qtrs
Total cost of product and clinical laboratory service revenues	`CostOfRevenue`	$3.66M	USD	1 Quarter
Total cost of product and clinical laboratory service revenues	`CostOfRevenue`	$940.57K	USD	1 Quarter
Total cost of product and clinical laboratory service revenues	`CostOfRevenue`	$6.72M	USD	2 Qtrs
Total cost of product and clinical laboratory service revenues	`CostOfRevenue`	$1.46M	USD	2 Qtrs
Gross profit	`GrossProfit`	$2.83M	USD	2 Qtrs
Gross profit	`GrossProfit`	$1.73M	USD	1 Quarter
Gross profit	`GrossProfit`	$3.60M	USD	2 Qtrs
Gross profit	`GrossProfit`	$2.49M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$6.40M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$3.41M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$3.09M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$8.07M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.07M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.15M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.72M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$955.74K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$8.12M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$10.23M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$4.48M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$4.05M	USD	1 Quarter
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-6.63M	USD	2 Qtrs
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-2.32M	USD	1 Quarter
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-1.99M	USD	1 Quarter
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-5.29M	USD	2 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$8.40K	USD	2 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$5.81K	USD	2 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$13.84K	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$5.54K	USD	1 Quarter
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-1.77M	USD	2 Qtrs
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	2 Qtrs
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	-	USD	2 Qtrs
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	$839.95K	USD	2 Qtrs
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	$839.95K	USD	1 Quarter
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	-	USD	1 Quarter
Transaction cost allocated to warrant liabilities	`TransactionCostAllocatedToWarrantLiabilities`	-	USD	2 Qtrs
Transaction cost allocated to warrant liabilities	`TransactionCostAllocatedToWarrantLiabilities`	$-391.33K	USD	2 Qtrs
Transaction cost allocated to warrant liabilities	`TransactionCostAllocatedToWarrantLiabilities`	$-391.33K	USD	1 Quarter
Transaction cost allocated to warrant liabilities	`TransactionCostAllocatedToWarrantLiabilities`	-	USD	1 Quarter
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	$-782.50K	USD	2 Qtrs
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	-	USD	2 Qtrs
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	$-782.50K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-108.73K	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-54.87K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-162.17K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-250.22K	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-6.48M	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.52M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.76M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-6.32M	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-6.48M	USD	2 Qtrs
NET LOSS	`ProfitLoss`	$-4.72M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-6.32M	USD	2 Qtrs
NET LOSS	`ProfitLoss`	$-1.76M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-1.52M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-4.81M	USD	1 Quarter
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$2.22K	USD	2 Qtrs
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.11K	USD	1 Quarter
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-278.00	USD	1 Quarter
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-257.00	USD	2 Qtrs
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-1.76M	USD	1 Quarter
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-1.52M	USD	1 Quarter
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-6.48M	USD	2 Qtrs
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-6.33M	USD	2 Qtrs
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	$110.11K	USD	1 Quarter
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	-	USD	1 Quarter
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	-	USD	2 Qtrs
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	$110.11K	USD	2 Qtrs
NET LOSS attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.52M	USD	1 Quarter
NET LOSS attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.87M	USD	1 Quarter
NET LOSS attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-6.59M	USD	2 Qtrs
NET LOSS attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-6.33M	USD	2 Qtrs
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-0.21	USD	1 Quarter
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-0.23	USD	1 Quarter
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-1.00	USD	2 Qtrs
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-0.85	USD	2 Qtrs
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-0.23	USD	1 Quarter
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-0.21	USD	1 Quarter
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-0.85	USD	2 Qtrs
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-1.00	USD	2 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	8.08M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	7.24M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	7.78M	shares	2 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	6.34M	shares	2 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	7.78M	shares	2 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	6.34M	shares	2 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	8.08M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	7.24M	shares	1 Quarter

Cash Flow Statement 72 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-6.48M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-4.72M	USD	1 Quarter
Net loss	`ProfitLoss`	$-6.32M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-1.76M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.52M	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.81M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$296.79K	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$641.62K	USD	2 Qtrs
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	$-1.77M	USD	2 Qtrs
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	-	USD	2 Qtrs
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	-	USD	2 Qtrs
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	$839.95K	USD	2 Qtrs
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	$839.95K	USD	1 Quarter
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	-	USD	1 Quarter
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	$-782.50K	USD	2 Qtrs
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	-	USD	2 Qtrs
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Unrealized gain on change in fair value of the Common Warrants	`FairValueAdjustmentOfWarrants`	$-782.50K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$1.22M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$1.97M	USD	2 Qtrs
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$10.00K	USD	2 Qtrs
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$19.64K	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$2.01M	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-206.23K	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$-725.97K	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$223.17K	USD	2 Qtrs
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$842.07K	USD	2 Qtrs
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-13.09K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$472.20K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-1.19M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$-160.98K	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$112.66K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.96M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-7.43M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$170.22K	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.14M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.14M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-170.22K	USD	2 Qtrs
Net proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	2 Qtrs
Net proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$2.61M	USD	2 Qtrs
Net proceeds from issuance of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	$13.76M	USD	2 Qtrs
Net proceeds from issuance of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	$4.09M	USD	2 Qtrs
Repayment of convertible notes	`RepaymentsOfConvertibleDebt`	-	USD	2 Qtrs
Repayment of convertible notes	`RepaymentsOfConvertibleDebt`	$1.67M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$14.70M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$4.09M	USD	2 Qtrs
Net (decrease) increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-42.16K	USD	2 Qtrs
Net (decrease) increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$6.14M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.55M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.93M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.79M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.51M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.55M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.93M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.79M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.51M	USD	Point-in-time
Cash paid during period for interest	`InterestPaidNet`	-	USD	2 Qtrs
Cash paid during period for interest	`InterestPaidNet`	-	USD	2 Qtrs
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	2 Qtrs
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	2 Qtrs
Interest paid in kind	`PaidInKindInterest`	$28.33K	USD	2 Qtrs
Interest paid in kind	`PaidInKindInterest`	-	USD	2 Qtrs
Deemed dividend warrant modifications	`DeemedDividendWarrantModifications`	$110.11K	USD	2 Qtrs
Deemed dividend warrant modifications	`DeemedDividendWarrantModifications`	-	USD	2 Qtrs
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	$76.18K	USD	2 Qtrs
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	$256.19K	USD	2 Qtrs
Issuance of stock options for payment of accrued bonus	`IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus`	-	USD	2 Qtrs
Issuance of stock options for payment of accrued bonus	`IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus`	$300.00K	USD	2 Qtrs
Fair value of warrants issued	`FairValueOfWarrantsIssued`	$1.07M	USD	2 Qtrs
Fair value of warrants issued	`FairValueOfWarrantsIssued`	$3.35M	USD	2 Qtrs

Stockholders Equity 33 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.39M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.62M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.72M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$7.65M	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	7.49M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	8.23M	shares	Point-in-time
Common stock issued in public offering, net of offering costs	`SharesIssuedInPublicOffering`	$-13.76M	USD	1 Quarter
Common stock issued in public offering, net of offering costs	`SharesIssuedInPublicOffering`	$-4.09M	USD	1 Quarter
Exercise of warrants	`StockIssuedDuringPeriodValueWarrantsExercised`	$8.40K	USD	1 Quarter
Exercise of warrants	`StockIssuedDuringPeriodValueWarrantsExercised`	$2.61M	USD	1 Quarter
Fair value of warrants issued in connection with public offering	`WarrantsIssuedDuringPeriodValueWarrants`	$-3.35M	USD	1 Quarter
Fair value of warrants issued in connection with public offering	`WarrantsIssuedDuringPeriodValueWarrants`	$1.64M	USD	1 Quarter
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$649.25K	USD	1 Quarter
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.70M	USD	1 Quarter
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$571.50K	USD	1 Quarter
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$272.92K	USD	1 Quarter
Options issued in settlement of accrued bonus	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$300.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-6.48M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-4.72M	USD	1 Quarter
Net loss	`ProfitLoss`	$-6.32M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-1.76M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.52M	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.81M	USD	1 Quarter
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.39M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.62M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.72M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$7.65M	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	7.49M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	8.23M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.